How to use the speech recognition tool?



Rate of Progression in USH2A Related Retinal Degeneration.

Type: Observational

Status of the trial: Active, Not recruiting

Orphan Drug Recognition: NA


  • Opening Date: 2017-08-01
  • Closing Date: 2021-12-31


Inclusion: Participants with clinical diagnosis of rod-cone degeneration and at least 2 pathogenic or likely pathogenic mutations in USH2A gene; age ≥ 8 years

Exclusion: Mutations in genes that cause autosomal dominant RP, X-linked RP, or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than USH2A; Expected to enter experimental treatment trial at any time during this study; History

More information

Children: Yes

Adults: Yes

Funder Type: patient organisation

Within ERN-EYE members

Principal investigators

Other investigators


  • Retinal Rare Eye Diseases (WG1)


* indicates required

This ERN is supported by: